Durvalumab is a human IgG1 monoclonal antibody immune checkpoint inhibitor marketed as Imfinzi and used across multiple cancers including lung, biliary tract, bladder, endometrial, and gastric/GEJ settings. It targets PD-L1 and blocks PD-L1 interactions with PD-1 and CD80 on T cells. The product has U.S. approvals since 2017 with continued indication expansions.
Meta-analysis of 24 trials found chemoimmunotherapy improved survival in PD-L1-high advanced NSCLC. PPIs and antibiotics were linked to worse durvalumab outcomes, and a chronotherapy trial was retracted.
Hengrui Medicine won NMPA clearance for a Phase II NSCLC trial combining SHR-A2009 ADC with adebrelimab or EGFR-TKI, and with partner Kailera reported up to 12.1% weight loss in a Phase II obesity study of oral ribupatide. SHR-A2009 monotherapy NDA is under review for NSCLC, and cumulative R&D on SHR-A2009 has reached RMB 330 million.
A phase one trial of RSO-021 achieved disease control in 67% of relapsed mesothelioma patients. Other advances include daraxonrasib for NRAS-driven melanoma, an aneuploidy biomarker for PARP inhibitor response in childhood cancers, and new research into a cancer target and cholangiocarcinoma treatment.
ASCO 2026 data show CBM588 boosts immunotherapy in kidney cancer and a bispecific combo improves lymphoma. Early-day ICI infusion, mezigdomide T cell reinvigoration, and dostarlimab maintenance also advance cancer immunotherapy.
The phase 3 RAMPART trial updated results show adjuvant durvalumab monotherapy did not significantly improve disease-free survival in resected renal cell carcinoma, while the durvalumab plus tremelimumab combination showed benefit in high-risk patients. Real-world treatment decisions are also shaped by patient-specific factors.
Two studies report on thoracic radiotherapy for lung cancer: a phase III trial found adding radiotherapy to chemoimmunotherapy did not improve survival in extensive-stage small cell lung cancer, while a retrospective review showed high local control rates with single-fraction 28 Gy stereotactic body radiotherapy.
Dual immunotherapy allowed 70.6% of MSI-H gastric cancer patients to avoid surgery in the INFINITY trial. German off-label immunotherapy shows 20-25% response rates, requiring careful patient selection.
European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.
Durvalumab has been approved for rollout on the NHS for muscle-invasive bladder cancer. In a trial of more than 1,000 patients, it cut the risk of progression by 32% versus standard care.
Moderna and Merck advance a Phase 2 trial of mRNA cancer vaccine V940 with pembrolizumab and chemotherapy for metastatic squamous NSCLC. In biliary tract cancer, first-line treatment combines chemotherapy with immunotherapy, while targeted therapy resistance prompts liquid biopsy. ImmunityBio tests a chemotherapy-free NK-cell regimen in non-Hodgkin lymphoma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07766187 |
Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07765433 |
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07759492 |
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07720284 |
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC |
RECRUITING | PHASE3 |
| NCT07718139 |
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada |
ACTIVE_NOT_RECRUITING | |
| NCT07710885 |
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer |
RECRUITING | PHASE3 |
| NCT07672223 |
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07639528 |
Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07637513 |
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07625930 |
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial |
NOT_YET_RECRUITING | PHASE2 |
